BLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOLLISTIM (follitropin alfa/beta) is a recombinant human follicle-stimulating hormone (FSH) administered via intramuscular or subcutaneous injection. It is indicated for ovulation induction and assisted reproductive technologies (ART) in women with infertility. The drug mimics endogenous FSH to stimulate follicular development and oocyte maturation.
LOE Approaching
As a mature biologic approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension and managing market share erosion rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
Started Jan 2009
110 enrolled
Polycystic Ovarian SyndromeInfertility
MENOPUR® Versus FOLLISTIM®
Started Dec 2008
173 enrolled
Infertility
Career Relevance
Working on FOLLISTIM positions you in a mature reproductive health franchise facing LOE headwinds; career impact emphasizes defensive commercial strategies, payer negotiations, and lifecycle management expertise. This role is suited for professionals comfortable navigating competition and preparing market transitions rather than launching new products.
Brand Manager
Worked on FOLLISTIM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.